Manhattan Associates, Inc. (MANH) vs Novo Nordisk A/S (NVO)
A side-by-side comparison of Manhattan Associates, Inc. and Novo Nordisk A/S across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 11, 2026. Differences are shown without an overall score or investment verdict.
Different business models: MANH is classified in Technology; NVO is classified in Healthcare. Margin, capital intensity, and valuation differences should be interpreted in that sector context.
MANH
Manhattan Associates, Inc.
$201.82TechnologyDelayed quote: Sep 11, 2026, 4:00 PM EDT
NVO
Novo Nordisk A/S
$43.07HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — MANH vs NVO
growth of $100 · dividends reinvested · last 10yMANH +233.0% (+12.8%/yr)NVO +140.9% (+9.2%/yr)MANH compounded faster over this window
MANH NVO
MANH vs NVO: by the numbers
- •NVO is the larger company ($191.26B vs $11.77B market cap).
- •NVO trades at the lower trailing earnings multiple (10.61 vs 57.83 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (35.33% vs 18.67% net margin).
- •NVO grew revenue faster over the past five years (19.76% vs 12.69% CAGR).
- •NVO pays a dividend (4.08% yield), while MANH has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | MANH | NVO |
|---|---|---|
| P/E ratio | 57.83 | 10.61 |
| Forward P/E | 36.71 | N/A |
| P/S ratio | 10.45 | 3.75 |
| P/B ratio | 74.71 | 5.67 |
| EV / EBITDA | 41.45 | 7.85 |
| FCF yield | 3.39% | 3.89% |
Profitability
| Metric | MANH | NVO |
|---|---|---|
| Gross margin | 54.65% | 80.64% |
| Operating margin | 24.33% | 43.10% |
| Net margin | 18.67% | 35.33% |
| ROE | 133.48% | 53.50% |
| ROIC | 90.92% | 30.21% |
Dividends
| Metric | MANH | NVO |
|---|---|---|
| Dividend yield | N/A | 4.08% |
| Payout ratio | N/A | 44.27% |
Growth (annualized)
| Metric | MANH | NVO |
|---|---|---|
| Revenue CAGR (5Y) | 12.69% | 19.76% |
| EPS CAGR (5Y) | 21.59% | 19.59% |
| FCF CAGR (5Y) | 19.51% | -1.45% |
| Total return CAGR (5Y) | 4.78% | -0.22% |
Frequently asked
- Which has the lower trailing P/E, MANH or NVO?
- NVO has the lower trailing P/E: MANH trades at 57.83 and NVO at 10.61. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, MANH or NVO?
- Over the past five years, NVO grew revenue faster — MANH at a 12.69% CAGR versus NVO at 19.76%.
- Does MANH or NVO pay a bigger dividend?
- NVO pays a dividend (4.08% yield), while MANH has no payments in the available dividend history.
- Is MANH or NVO more profitable?
- NVO runs the higher net margin — MANH at 18.67% versus NVO at 35.33%.
- How have MANH and NVO total returns compared?
- Over the past 10 years, MANH delivered 13.30% and NVO delivered 9.70% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Manhattan Associates P/E ratioNovo Nordisk A/S P/E ratioNovo Nordisk A/S dividend yieldManhattan Associates ROENovo Nordisk A/S ROEManhattan Associates operating marginNovo Nordisk A/S operating marginManhattan Associates revenue growthNovo Nordisk A/S revenue growthManhattan Associates free cash flowNovo Nordisk A/S free cash flow
Manhattan Associates & Novo Nordisk A/S appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 11, 2026.